After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline.
Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback